Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

Technological advances empower the modification of NK cells and renewed potential for therapeutic uses in cancer and ...

Basel: Roche has announced that the company has received approval from the European Commission for Columvi (glofitamab) in ...

DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted ...

Zenas BioPharma, Inc.'s obexelimab's potential in treating autoimmune diseases and upcoming phase 2 & 3 trial results. Read ...

BriaPro has filed US patent applications for this technology ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted ...

At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address autoimmune and inflammatory conditions.

Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...